News & Media

News & Media

Press releases

February 4, 2019
Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer

January 18, 2019
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies

December 19, 2018
Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with Merck

March 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

In the news

Xconomy
Despite Buyout, Celgene Dealmaking Rolls On With Kyn, Obsidian Tie-Ups

Endpoints News
Celgene inks first deals since Bristol-Myers announced $74B buyout — bets $80M on immunometabolism

Boston Business Journal
Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup

Bloomberg
Bloomberg Baystate Business: Biogen, Budget and ESG

view all Tweets

Twitter

@KynTherapeutics
#DYK you can now view the latest news coverage of our team, our science and our ongoing work on our website? Take a… http://qBsc7ToT9z

@KynTherapeutics
#MeetTheTeam: Our VP of business development, @maude_tessier, visits elderly residents at @H_SeniorLife with her do… http://Yc5KzU1LJ2

@KynTherapeutics
We’re seeking a new, energetic and resourceful Business Development team member! #biotechjobs Click here for more i… http://4RSpj9M69Z

@KynTherapeutics
Attending the @KeystoneSymp conference on cancer immunotherapy? Our VP of Biology Michelle Zhang will share insight… http://Q1wbkgGwSX

Corporate fact sheet

download now

Media contact

Tom Donovan
Ten Bridge Communications
857-559-3397
tom@tenbridgecommunications.com

Alerts

Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
50 Northern Avenue
7th Floor
Boston, MA 02210

Call us

1-857-273-8343

Email us

info@kyntherapeutics.com

Friend us

LinkedIn